Boyer David W.

Boyer David W., Chief Corporate Affairs Officer at Neurocrine Biosciences (NBIX), has demonstrated a consistent pattern of selling activity in the company’s stock over multiple years, with no recorded purchases. According to SEC Form 4 filings, Boyer has executed 33 transactions exclusively involving NBIX, all of which were sales or related dispositions, totaling over $2.54 million in proceeds. Recent filings show a continuation of this trend, with five sales in early 2026, including a $667,517 disposition on February 13 and smaller transactions ranging from $103,267 to $161,775 in late January and early February. The transactions appear to follow a recurring schedule, with notable activity around mid-February in multiple years, such as sales totaling $208,387 on February 13, 2025, and $147,190 in October 2024. The filings indicate that Boyer’s transactions are primarily tied to stock awards (code "F") and open-market sales (code "S"), with no recent buying activity. The absence of purchases and the repeated liquidation of holdings suggest a long-term divestment strategy rather than accumulation. While the sales are substantial—particularly the $667,517 transaction in February 2026—they appear methodical rather than abrupt, often coinciding with vesting events. The consistency of these disposals, spanning multiple years, underscores a clear directional bias toward reducing exposure to NBIX stock, though the reasons behind this pattern remain undisclosed in the filings.